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Abstract
Background and Aims: To describe the biology of alveolar bone regeneration.
Material and Methods: Four comprehensive reviews were performed on (a) mesen-
chymal cells and differentiation factors leading to bone formation; (b) the critical in-
terplay between bone resorbing and formative cells; (c) the role of osteoimmunology 
in the formation and maintenance of alveolar bone; and (d) the self- regenerative ca-
pacity following bone injury or tooth extraction were prepared prior to the workshop.
Results and Conclusions: This summary information adds to the fuller understand-
ing of the alveolar bone regenerative response with implications to reconstructive 
procedures for patient oral rehabilitation. The group collectively formulated and ad-
dressed critical questions based on each of the reviews in this consensus report to 
advance the field. The report concludes with identified areas of future research.
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1  | PRE AMBLE
The remit of Group I was to describe the biology of alveolar bone 
regeneration. The focus was made on the molecular and cellular pro-
cesses of intramembranous bone regeneration of the alveolus fol-
lowing injury (such as subsequent to tooth extraction) or diseases 
(occurring around teeth or dental implants). The interface of the 
periodontal ligament and cementum as a part of periodontal regen-
eration was not addressed. However, with respect to bone regen-
eration, it may include both the alveolar bone and/or the alveolar 
bone proper in the case of tooth- supporting bone regeneration. 
The group considered the bone regenerative process in systemically 
healthy individuals contrasted with compromised wound healing af-
fected at the local or systemic levels. Bone regeneration was defined 
as the re- growth or reconstitution of a lost or damaged bone to re-
store its former architecture and function, whilst bone remodelling 
was considered as the physiologic remodelling of bone that takes 
place in a biologically coupled system of activation, resorption and 
formation (Broggini et al., 2007).
The evidence focused on in vitro and in vivo models of bone re-
generation to better understand the biological basis of alveolar bone 
regeneration. The group identified early stage, pre- clinical in vivo 
models as well as those with a closer translation to the human clinical 
situation. Human studies available for evaluation were few.
The report was based on four comprehensive reviews on (a) 
mesenchymal cells and differentiation factors leading to bone 
formation (Bartold, Gronthos, Haynes, & Ivanovski, 2019); (b) 
the critical interplay between bone resorbing and formative cells 
(Lerner, Kindstedt, & Lundberg, 2019); (c) the role of osteoimmu-
nology in the formation and maintenance of alveolar bone (Gruber, 
2019); and (d) the self- regenerative capacity following bone injury 
or tooth extraction (Sculean, Stavropoulos, & Bosshardt, 2019). 
These works add to the fuller understanding of the alveolar bone 
regenerative response with implications to reconstructive proce-
dures for patient rehabilitation. The group collectively formulated 
and addressed critical questions based on each of the reviews in 
this consensus report. The group also identified areas of future 
research.
Q1. What are the critical biological phases 
characterizing bone regeneration?
Alveolar bone regeneration follows a temporal series of events 
(Araujo, Silva, Misawa, & Sukekava, 2015; Bastian et al., 2011; 
Stegen, van Gastel, & Carmeliet, 2015):
• Haemostasis and establishment of the blood coagulum
• Inflammatory phase
• Angiogenesis: cellular recruitment and capillary ingrowth
• Mesenchymal cell recruitment, provisional non-mineralized ma-
trix deposition followed by interactive processes involving min-
eralization, bone-forming cell differentiation and finally bone 
formation
o Role of growth and differentiation factors
o Processes of woven and lamellar bone formation
• Remodelling of newly formed bone; coupling of osteoclasts and 
osteoblasts which continues throughout life.
Other critical events identified at the molecular and cellular levels need 
to be explored before definite conclusions defining the sequence of 
events involved in bone regeneration can be made.
Q2. What biologic/growth factors are involved in the 
bone regeneration process?
Growth and differentiation factors/signalling molecules are well 
documented in pre- clinical in vivo models (table 2; Bartold et al., 
2019) but less well characterized for humans.
Major growth and differentiation factors identified to date 
include
• Bone-derived Growth Factors and Differentiation Factors
Bone morphogenetic proteins (BMPs) 
BMP-2
BMP-7
Growth differentiation factors (GDFs)
Platelet-derived growth factor (PDGF-BB)
Fibroblast growth factors (FGFs) 
aFGF
FGF-2
Transforming growth factor-β (TGF-β)
Insulin-like growth factors (IGFs) 
IGF-1
IGF-2
Vascular endothelial cell growth factor (VEGF)
Skeletal growth factor (SGF)
Parathyroid hormone-related peptide (PTHrP)





• Bone Growth and Regeneration Families of Transcription Factors
Homeobox gene family of transcription factors
Dlx homeobox gene family
K E Y W O R D S
bone remodelling, bone turnover, osteogenesis, osteoimmunology, regenerative medicine, 
wound healing
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Homeobox gene family
Hox homeobox gene family
Paired box (Pax) homeobox gene family
LIM homeobox gene family (Lhx)
Paired-like (Pitx) homeobox gene family
Runx transcription factors
SRY-related HMG-box family of transcription factors
bHLH family of transcription factors
Twist
D proteins
The myogenic regulatory factors (MRFs)




Forkhead family of transcription factors
Q3. What is the role of mesenchymal stem cells, their 
niche and extracellular matrix in bone regeneration?
Mesenchymal stem cells provide the reservoir for new bone- forming 
cells.
Niches associated with the alveolar bone (e.g. marrow and peri-
osteal locales) provide potential sources and environment of MSC 
for bone regeneration and include blood, perivascular source, cells 
lining the wall of bone defect and periosteum. These provide a 
source of pluripotent stem cells capable of differentiating and initi-
ating tissue regeneration.
Critical to tissue regeneration is the production of a new extra-
cellular matrix that provides the environment for subsequent cell dif-
ferentiation and neo- ossification. Thus, the role of the extracellular 
matrix is to provide a platform for the initiation of tissue- specific 
regeneration. Fibrous and non- fibrous elements of the extracellular 
matrix provide a number of critical functions central to tissue regen-
eration and include
• A reservoir of growth and differentiation factors that can be re-
leased in well-controlled spatial and temporal sequences;
• Induction of angiogenesis;
• Homing signals for mesenchymal stem cells;
• Bioactive space maintaining matrix for cell differentiation; and
• An environment of both osteoinduction and osteoconduction.
Q4. What coupling factors regulate bone remodelling?
Coupling between bone resorption and bone formation refers to the 
process in which osteoclastic bone resorption is linked to the differ-
entiation of osteoblasts and their bone- forming activity. This process 
is mediated by factors released from the bone matrix during bone re-
sorption, that is, soluble and membrane products of the osteoclasts 
and signals from osteocytes and osteoblasts. Osteoclast- derived 
factors include BMP6, WNT 10b, CT- 1 and S- 1- P; matrix- derived 
factors include BMPs, TGF- β, IGF- 1, FGFs, EGFRs and its ligands 
as well as miRNAs. Osteocyte/osteoblast- derived factors include 
sclerostin, Dickkopf- 1, WNT- 1, RANKL/OPG and PTHrp. Combined 
osteocyte/osteoblast and osteoclast factors include semaphorins, 
ephrins and ephrin receptors.
Q5. What coupling factors involved in bone 
remodelling have regenerative potential for clinical 
use?
BMP- 2 and BMP- 7 are in clinical use and BMP- 5, BMP- 6, BMP- 9 
exhibit osteogenic properties. Currently, the most studied signal-
ling pathway associated with bone regeneration is the WNT system. 
Neutralizing antibodies to sclerostin have been demonstrated to in-
crease bone mass in phase III studies. Other factors with potential 
for regeneration are described in detail in reports from Group 2.
Q6. What is the role of inflammation and its 
resolution in the process of bone regeneration?
There is a large body of data from pre- clinical models supporting 
the general concept that inflammation is an important component of 
bone regeneration. Data need to be interpreted carefully as fracture 
and osteotomy defect models were utilized involving long bones and 
genetically distinct murine models. However, genetic ablation of 
cyclooxygenase- 2 (COX- 2) in rodents treated with COX- 2- selective 
non- steroidal anti- inflammatory drugs led to impaired fracture heal-
ing (Simon, Manigrasso, & O'Connor, 2002) that could be rescued by 
activation of prostaglandin E2 receptor subtype 4 (Xie et al., 2009). 
Mice lacking the 5- lipoxygenase gene (Manigrasso & O'Connor, 
2010) and systemic inhibition of 5- lipoxygenase were associated 
with increased bone regeneration. In addition, TNF- α receptor- 
deficient animals and systemic administration of anti- TNF led to im-
paired fracture healing. Application of low concentrations of TNF- α 
promotes fracture repair. Moreover, IL6 and IL17A knockout animals 
display impaired fracture healing.
There is emerging evidence from pre- clinical in vivo studies in small 
and large animals that pro- resolving lipid mediators such as RvE1 and 
LxA4 have positive modulatory effects on bone regeneration, beyond 
their inflammation- resolving properties. These appear to be receptor- 
mediated (ERV1 and BLT- 1) and reduce osteoclast differentiation and 
activation, whilst at the same time promoting osteoblast- mediated 
healing. The presence of RvD1 in the acute phase of the inflammatory 
response to an implanted biomaterial had a positive role in subsequent 
bone tissue repair (Vasconcelos et al., 2018).
Q7. What is the role of different macrophage 
phenotypes, in particular osteomacs, in bone 
regeneration?
Pre- clinical models support a critical role for macrophages in bone 
regeneration. Macrophage depletion by Fas- induced apoptosis in 
mice or clodronate liposome delivery showed impaired intramem-
branous osteotomy defects and endochondral bone regeneration 
     |  9GIANNOBILE Et AL.
in fracture models. Depletion of CD169 expressing macrophages 
(“Osteomacs”) led to impaired intramembranous and endochondral 
ossification (Batoon et al., 2017).
Q8. What is the role of lymphocytes in bone 
regeneration?
The majority of studies reviewed investigated the role of T and B 
lymphocytes in bone regeneration using fracture models. T and B 
lymphocytes infiltrate the fracture callus and participate in bone re-
modelling. Bone remodelling is accelerated in RAG1 knockout mice, 
which do not possess mature B and T lymphocytes. Similarly, others 
found RAG1 knockout mice to have a larger but lower density callus 
compared to controls (Nam et al., 2012). Depletion of CD8 T cells 
in a murine osteotomy model resulted in enhanced fracture regen-
eration, whereas a transfer of CD8 (+) T cells impaired the healing 
process (Reinke et al., 2013). In animals, deficient in γδ T cells, bone 
regeneration was inhibited. The absence of B cells in mice does not 
compromise bone formation in a tibial injury model (Raggatt et al., 
2013). It appears therefore that heterogeneity exists in T- cell behav-
iour, with some T- cell populations influencing osteolysis, whereas 
others (γδ T cells) are associated with enhanced bone formation.
Q9. What is the role played by osteoclasts in bone 
regeneration?
Bone resorption occurs as an important stage in the regeneration 
process (Vasak et al., 2014). The molecular mechanisms underpinning 
this process may be initiated by the release of induction signals for 
osteoclastogenesis by apoptotic osteocytes and subsequent resorp-
tion of necrotic elements of the alveolar bone (Cha et al., 2015; Chen 
et al., 2018). In contrast to bone remodelling, bone formation within 
osteotomy sites or micro- cracks is not a coupled process and can arise 
independently of bone resorption. Knowledge of the role played by 
osteoclasts in bone regeneration is derived from studies employing 
bisphosphonates and RANKL activity blockade. Bisphosphonate ad-
ministration and RANKL blockade using Denosumab increased frac-
ture callus volume with a retained trabecular bone structure in rodents 
(Amanat, McDonald, Godfrey, Bilston, & Little, 2007; Gerstenfeld et al., 
2009). Moreover, bisphosphonate use and RANKL activity blockade 
also increased bone formation in osteotomy defects (Bernhardsson, 
Sandberg, & Aspenberg, 2015) and supported early bone formation 
around implants (Aspenberg, 2009). The available literature supports 
the contention that early bone formation does not appear to require 
osteoclasts, but bone maturation requires bone remodelling and thus 
the coupling of osteoclast to osteoblast function.
Q10. Does bone regeneration in alveolar extraction 
sites in animals reflect the clinical situation in 
humans?
The sequential phases of regeneration after tooth extraction ap-
pear to be similar among rodents, canines, non- human primates and 
humans. However, bone remodelling in general takes a longer time 
in humans as compared to the other species.
Q11. Does the morphology and location of the defect 
affect the regenerative capacity?
The available data indicate that defect morphology (e.g. number of 
bony walls and defect dimensions, that is depth, width and volume), 
location (e.g. extraction sockets, periapical, symphysis or ramus 
donor sites), and closed or open healing environment substantially 
influence regeneration of bone defects. Data indicate that the cells 
responsible for bone regeneration originate from the surrounding 
bony walls and periosteum. Blood supply, wound stability and avail-
ability of cells are influenced by defect morphology and location.
Q12. What is the regenerative capacity of cystic 
defects or intra- oral bone graft donor sites?
Defects following periapical surgery or cystectomy possess a sub-
stantial self- regenerative capacity and largely heal with bone in the 
vast majority of cases without the use of any adjunct measures. 
The strong intrinsic potential for regeneration of bone defects after 
periapical surgery or cystectomy is most likely due to their favour-
able morphology and location. At bone graft donor sites such as the 
mandibular symphysis or ramus, repair of the defects following bone 
block harvesting is generally incomplete. There are no data to draw 
conclusions on the size of the defect that is critical for complete re-
generation in cystic or intra- oral bone graft donor sites.
2  | FUTURE RESE ARCH
Future research efforts will need to target both stem cells and bio-
logics through well- controlled clinical trials based on the in vitro and 
pre- clinical studies published to date. Combining cell- based thera-
pies with controlled temporal delivery of regulatory molecules, using 
tissue engineering approaches, offers many exciting prospects for 
bone regeneration. It is not until we understand the process of for-
mation that regeneration will become an achievable and predictable 
clinical endpoint for managing disease and trauma. This will certainly 
be the case for bone regeneration.
For cell and biological therapies, manipulation of extracellular ma-
trix to enhance regenerative outcomes will be of value and include 
identify stem cell niches and the influence that different niches have 
on the ultimate phenotype of stem cell differentiation; understanding 
mechanisms of cell–cell and cell–matrix communication through the 
secretome; explore lab- on- a- chip technologies as matrix modulation 
models that may substitute for pre- clinical in vivo studies.
Pre- clinical models to study molecular mechanisms of bone re-
generation will be developed. These will include models testing the 
role of single mediators or pathways using technology such as point 
mutations, gene deletion or gene over- expression. In addition, the 
field will benefit from molecules with possible future therapeutic 
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use such as antibodies, inhibitors or small RNAs. A major challenge 
with several of these agents lies in the delivery and targeting to the 
site as well as the management of potential off- target side effects.
Macrophages demonstrate significant plasticity in model sys-
tems and respond to various environmental cues and other molec-
ular signals that influence differentiation into either type- 1 (M1) or 
type- 2 (M2) cells. The association of the M1 phenotype with pro- 
inflammatory responses and the M2 class with anti- inflammatory 
and/or pro- resolving activities is rather simplistic and requires fur-
ther research. Emerging evidence indicates that induction of the M2 
phenotype is associated with decreased expression of RANKL and a 
reduced number of osteoclasts (Zhuang et al., 2019). However, the 
role of M1 and M2 cells in bone regeneration requires further re-
search. In addition, the use of cytokines, chemokines, transcription 
factors and micro- RNAs to influence a shift in the balance of M1 and 
M2 macrophages for bone regeneration is worthy of investigation.
More information is needed on modifying factors that affect re-
generation of bone (such as epigenetic influences, ageing (inflam-
maging), smoking, drugs and systemic conditions). The role of the gut 
and oral microbiomes in bone regeneration remains to be explored. 
Potential avenues need to account for interactions between the mi-
crobiome and the osteoimmune response in order to determine spe-
cific biological pathways.
More information is needed on the influence of defect morphol-
ogy, location and closed or open healing environments, on bone regen-
eration in extraction sites, cystic and intra- oral bone graft donor sites.
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